Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG2000 micelles

International Journal of Nanomedicine

Volumn 9, Issue 1, 2013, Pages 243-255

  Cai, Lu Lu ^a   Qiu, Neng ^b   Xiang, Ming Li ^c   Tong, Rong Sheng ^a   Yan, Jun Feng ^a   He, Lin ^a   Shi, Jian You ^a   Chen, Tao ^d   Wen, Jiao Lin ^c   Wang, Wen Wen ^c   Chen, Li Juan ^c  

^a SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHENGDU UNIVERSITY OF TECHNOLOGY   (China)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antitumor; Gambogic acid; Micelle; Poly(ethylene glycol) drug conjugate; Toxicity

Indexed keywords

GAMBOGIC ACID; MACROGOL 2000;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MICELLIZATION; MOLECULAR MODEL; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; SURVIVAL TIME;

ANTITUMOR; GAMBOGIC ACID; MICELLE; POLY(ETHYLENE GLYCOL)-DRUG CONJUGATE; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WATER; CELL LINE, TUMOR; DRUG SYNERGISM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICELLES; NANOCAPSULES; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; SOLUBILITY; TREATMENT OUTCOME; XANTHONES;

EID: 84891537870     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S54050     Document Type: Article

References (54)

1. Auterhoff H, Frauendorf H, Liesenklas W, Schwandt C. [The chief constituents of gamboge resins. 1. Chemistry of gamboge]. Arch Pharm. 1962;295:833-846. German.
2. Ollis WD, Ramsay MVJ, Sutherland IO, Mongkolsuk S. The constitution of gambogic acid. Tetrahedron. 1965;21:1453-1470.
3. Cai SX, Jiang S, Zhang HZ, inventors. Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis. World Intellectual Property Organization Patent Application PCT/US2004/042292. December 17, 2004.
4. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004;27: 998-1003.
5. Yu J, Guo QL, You QD, et al. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother Pharmacol. 2006;58: 434-443.
6. Guo QL, Lin SS, You QD, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sci. 2006;78:1238-1245.
7. Liu W, Guo QL, You QD, Zhao L, Gu HY, Yuan ST. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J Gastroenterol. 2005;11:3655-3659.
8. Qiang L, Yang Y, You QD, et al. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol. 2008;75:1083-1092.
9. Yang Y, Yang L, You QD, et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007;256:259-266.
10. Sun S Y, Yue P, Kelloff GJ, et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl) retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers. 2001;10:595-601.
11. Liu YT, Hao K, Liu XQ, Wang GJ. Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin. 2006;27:1253-1258.
12. Hao K, Liu XQ, Wang GJ, Zhao XP. Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur J Drug Metab Pharmacokinet. 2007;32:63-68.
13. Dai JG, inventor. The preparation of a kind of gambogic acid injection. CN Patent No 03131511.9, Dec 5, 2003.
14. You OD, Guo QL, Ke X, et al, Inventors. The preparations of gambogic acid and its compound. CN Patent No 03132386.3, July 21, 2004.
15. Qi Q, You Q, Gu H, et al. Studies on the toxicity of gambogic acid in rats. J.Ethnopharmacol. 2008;117:433-438.
16. Han J, Xiao J, Wang H, et al. Measurement and correlation of taxol solubility in methanol, ethanol and methanol-water systems. J Chem Ind Eng. 2001;52:64-67.
17. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci. 2006;31:359-397.
18. Satchi-Fainaro R, Duncan R, Barnes CM. Polymer Therapeutics for Cancer: Current Status and Future Challenges. Polymer Therapeutics II. Berlin, Germany: Springer; 2006.
19. Li H, Huo M, Zhou J, et al. Enhanced oral absorption of paclitaxel in N-deoxycholic acid-N, O-hydroxyethyl chitosan micellar system. J Pharm Sci. 2010;99:4543-4553.
20. Hou L, Fan Y, Yao J, et al. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid. Carbohydr Polym. 2011;86:1157-1166.
21. Kwon GS, Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev. 1996;21:107-116.
22. Greenwald RB, Pendri A, Conover C, Gilbert C, Yang R, Xia J. Drug delivery systems. 2. Camptothecin 20-O-poly (ethylene glycol) ester transport forms. J Med Chem. 1996;39:1938-1940.
23. Sun M, Su X, Ding B, et al. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine. 2012;7:1085-1100.
24. Tang H, Murphy CJ, Zhang B, et al. Curcumin polymers as anticancer conjugates. Biomaterials. 2010;31:7139-7149.
25. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci. 2011;359:318-325.
26. Murphy CJ, Tang H, Van Kirk EA, Shen Y, Murdoch WJ. Reproductive effects of a pegylated curcumin. Reprod Toxicol. 2012;34:120-124.
27. Li J, Wang Y, Yang C, et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol. 2009;76:81-90.
28. Ceruti M, Crosasso P, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release. 2000;63:141-153.
29. Fleming AB, Haverstick K, Saltzman WM. In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem. 2004;15:1364-1375.
30. Tang X, Zhang P, Ye H, Zhang C, Shen W, Ping Q. Water-soluble gambogic acid PEGylated prodrugs: synthesis, characterization, physicochemical properties and in vitro hydrolysis. Pharmazie. 2008;63: 711-717.
31. Ding Y, Zhang P, Tang XY. PEG prodrug of gambogic acid: amino acid and dipeptide spacer effects. Polymer. 2012;53:1694-1702.
32. Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17: 490-519.
33. Hyper Chem. Professional version 8.0. Gainesville, FL, USA; Hypercube Inc; 2007.
34. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc. 1996;118:11225-11236.
35. Allinger NL. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc. 1977;99: 8127-8134.
36. Fletcher R, Reeves CM. Function minimization by conjugate gradients. Comput J. 1964;7:149-154.
37. Brooks BR, Bruccoleri RE, Olafson BD, et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem. 1983;4:187-217.
38. Brooks BR, Brooks CL, Mackerell AD, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30:1545-1614.
39. Ping QN, Zhang C, Ye H, et al. Polyethylene glycol prodrug of gambogic acid, its preparation method, formulation and use for preparing of drug. CN Patent No 100531801 C, Aug 26, 2009.
40. Tang N, Du G, Wang N, et al. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst. 2007;99:1004-1015.
41. Liu J, Xiao Y, Allen C. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 2004;93:132-143.
42. Liu J, Zahedi P, Zeng F, et al. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci. 2008;97: 3274-3290.
43. Lundberg BB, Risovic V, Ramaswamy M, et al. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release. 2003;86:93-100.
44. Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem. 1999;10:289-298.
45. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233: 134-144.
46. Greenwald RB. PEG drugs: an overview. J Control Release. 2001;74: 159-171.
47. Minko T. Soluble polymer conjugates for drug delivery. Drug Discov Today. 2005;2:15-20.
48. Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer. 2004;6:S85-S88.
49. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res. 1999;5:83-94.
50. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20:1668-1676.
51. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs. 2001;12:315-323.
52. Schoemaker NE, van Kesteren C, Rosing H, et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer. 2002;87:608-614.
53. Tofovic SP, Jackson EK. Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. J Cardiovasc Pharmacol. 1999;33:360-366.
54. Stoyanova E, Mitova V, Shestakova P, et al. Reversibly PEGylated nanocarrier for cisplatin delivery. J Inorg Biochem. 2013;120: 54-62.